UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
August 7, 2017
Date of Report (date of earliest event reported)
Cutera, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware |
000-50644 |
77-0492262 |
|
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
3240 Bayshore Blvd.
Brisbane, California 94005
(Address of principal executive offices)
(415) 657-5500
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On August 7, 2017, we are issuing a press release and holding a conference call regarding our financial results for the second quarter ended June 30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release of Cutera, Inc. dated as of August 7, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CUTERA, INC. |
|
|
|
|
||
|
Date: August 7, 2017 |
|
|
|
/s/ JAMES A. REINSTEIN |
|
|
|
|
|
James A. Reinstein |
|
|
|
|
|
President and Chief Executive Officer |
Exhibit 99.1
FOR IMMEDIATE RELEASE
CONTACTS:
Cutera, Inc.
Sandra Gardiner
Consultant Chief Financial Officer
415-657-5500
Investor Relations
John Mills
ICR, Inc.
646-277-1254
john.mills@icrinc.com
Cutera Reports Second Quarter 2017 Financial Performance, Increases Revenue and EPS Guidance and Expands Stock Buyback Program
Revenue Increases 32%, Achieves 12th Consecutive Quarter
of Year-over-Year Double-Digit Revenue Growth
BRISBANE, California, August 7, 2017 ─ Cutera, Inc. (NASDAQ: CUTR) (“Cutera” or the “Company”), a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide, today reported financial results for the second quarter ended June 30, 2017.
Key operating highlights and financial performance for the second quarter of 2017, when compared to the second quarter of 2016, were as follows:
|
● |
Revenue: |
|
✓ |
Increased 32%, to a second quarter record of $36.4 million, due primarily to 63% growth in North America product revenue; International product revenue also grew by 7% |
|
✓ |
Twelfth consecutive quarter of double-digit revenue growth |
|
✓ |
Growth experienced by multiple products, with particular strength from the recently launched truSculpt 3D body-sculpting platform |
|
● |
Gross margin was 58%, exceeding guidance by approximately 2%, primarily driven by sales of truSculpt 3D body sculpting system |
|
● |
Operating expenses declined as a percent of revenue from 63% to 53% |
|
● |
Net income was $1.9 million, compared to a net loss of $1.2 million |
|
● |
Earnings per diluted share increased to $0.13, compared to a loss of $0.09 |
|
● |
Cash generated by operations was $7.7 million. Cash, cash equivalents and investments totaled $53.2 million at June 30, 2017 |
|
● |
Stock repurchase program Board approved an incremental $25 million to be added to the presently active stock repurchase program. In Q2’17, the Company repurchased $4.1 million of stock bringing the total stock repurchased since February 2015 to 3.6 million shares, or $52.0 million |
James Reinstein, President and Chief Executive Officer of Cutera, stated, “We are pleased with the record level of second quarter revenue. This was coupled with significant improvement in several operating metrics, illustrating the organization’s ability to leverage the strong revenue. Our revenue growth of 32% was driven by multiple platforms within our product portfolio, with the launch of the truSculpt 3D product in North America being a significant driver of the growth and margin improvement this quarter. The truSculpt 3D also provides the Company with a new source of recurring revenue.
“Our Board’s approval to further expand our stock repurchase program reflects its confidence in our ability to build long-term value for shareholders. I believe that our financial performance in the second quarter of 2017, and our overall trajectory, demonstrates that Cutera is positioned to meet our short, medium and long term goals,” concluded Mr. Reinstein.
Product Updates
Initial market acceptance for the Company’s truSculpt 3D system is robust. Many practitioners continue to communicate to the Company that they believe it to be the best-in-class system for body sculpting. truSculpt 3D offers a new treatment method and higher frequency resulting in increased efficacy and greater fat destruction and circumferential reduction. It also includes a consumable revenue stream enabling the Company to share in the procedure income with its customers. This important technology improvement is critical for the Company to enable the truSculpt platform to become a more competitive offering in the body sculpting market. The Company expects to further enhance the platform in the second-half of this year and has already received FDA clearance for this new iteration. This next generation system will provide our customers with additional utility, efficacy and an improved return on their investment.
Full-Year 2017 Outlook
|
● |
Revenue guidance is being increased from $140 million to $144 - $147 million |
|
● |
Gross margin is expected to be in the range of 58% - 59% |
|
● |
Earnings per Share guidance is being increased to approximately $0.50 - $0.54 compared to the previous range of $0.45 - $0.50 |
|
● |
Repurchase sufficient shares to maintain the fully diluted share count at approximately 14.0 million for 2017 |
Conference Call
The conference call to discuss these results is scheduled to begin at 1:30 p.m. PST (4:30 p.m. EST) on August 7, 2017. Participating in the call will be James Reinstein, President and Chief Executive Officer, Sandra Gardiner, Consultant CFO, and Ron Santilli, outgoing CFO. The call will be broadcast live over the internet hosted at the Investor Relations section of Cutera's website at http://www.ir.cutera.com, and will be archived online within one hour of its completion through 8:59 p.m. PST (11:59 p.m. EST) on August 21, 2017. In addition, you may call 1-877-705-6003 if you wish to participate on the live call.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning Cutera's plans to introduce and commercialize new products, ability to increase revenue, improve financial results, grow the Company’s market share, realize benefits from additional investment, achieve financial guidance, plans for stock repurchase, expand market penetration, generate cash from operations, and statements regarding long-term prospects and opportunities in the laser and other energy-based equipment aesthetic market, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties that could affect Cutera's business and cause its financial results to differ materially from those contained in the forward-looking statements include those related to the Company’s efforts to improve sales productivity, hire and retain qualified sales representatives, improve revenue growth, gross margins and profitability through leveraging operating expenses; the Company’s ability to successfully develop and launch new products and applications and market them to both its installed base and new customers; unforeseen events and circumstances relating to the Company’s operations; government regulatory actions; and those other factors described in the section entitled, “Risk Factors” in its most recent Form 10-K as filed with the Securities and Exchange Commission ("SEC") on March 15, 2017 as well as subsequent reports and registration statements filed and furnished to the SEC from time to time. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. Cutera's financial performance for the second quarter ended June 30, 2017, as discussed in this release, is preliminary and unaudited, and subject to adjustment.
|
CUTERA, INC. |
||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||
|
(in thousands, except per share data) |
||||||||||
|
(unaudited) |
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2017 |
2016 |
2017 |
2016 |
|||||||||||||
|
Net revenue |
$ | 36,389 | $ | 27,477 | $ | 65,688 | $ | 49,900 | ||||||||
|
Cost of revenue |
15,343 | 11,472 | 29,121 | 21,421 | ||||||||||||
|
Gross profit |
21,046 | 16,005 | 36,567 | 28,479 | ||||||||||||
|
Gross margin % |
58 | % | 58 | % | 56 | % | 57 | % | ||||||||
|
Operating expenses: |
||||||||||||||||
|
Sales and marketing |
12,787 | 10,712 | 23,560 | 19,428 | ||||||||||||
|
Research and development |
2,981 | 2,712 | 5,926 | 5,421 | ||||||||||||
|
General and administrative |
3,548 | 3,997 | 6,764 | 7,217 | ||||||||||||
|
Total operating expenses |
19,316 | 17,421 | 36,250 | 32,066 | ||||||||||||
|
Income (loss) from operations |
1,730 | (1,416 | ) | 317 | (3,587 | ) | ||||||||||
|
Interest and other income, net |
276 | 217 | 549 | 361 | ||||||||||||
|
Income (loss) before income taxes |
2,006 | (1,199 | ) | 866 | (3,226 | ) | ||||||||||
|
Provision (benefit) for income taxes |
59 | 30 | (59 | ) | 54 | |||||||||||
|
Net income (loss) |
$ | 1,947 | $ | (1,229 | ) | $ | 925 | $ | (3,280 | ) | ||||||
|
Net income (loss) per share: |
||||||||||||||||
|
Basic |
$ | 0.14 | $ | (0.09 | ) | $ | 0.07 | $ | (0.25 | ) | ||||||
|
Diluted |
$ | 0.13 | $ | (0.09 | ) | $ | 0.06 | $ | (0.25 | ) | ||||||
|
Weighted-average number of shares used in per share calculations: |
||||||||||||||||
|
Basic and diluted |
13,935 | 13,131 | 13,888 | 13,071 | ||||||||||||
|
Diluted |
14,629 | 13,131 | 14,633 | 13,071 | ||||||||||||
|
CUTERA, INC. |
|||||||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||||
|
(in thousands) |
|||||||||
|
(unaudited) |
|
June 30, |
March 31, |
June 30, |
||||||||||
|
2017 |
2017 |
2016 |
||||||||||
|
Assets |
||||||||||||
|
Current assets: |
||||||||||||
|
Cash and cash equivalents |
$ | 18,679 | $ | 11,443 | $ | 7,420 | ||||||
|
Marketable investments |
32,270 | 36,990 | 35,902 | |||||||||
|
Restricted investments |
2,290 | - | - | |||||||||
|
Cash, cash equivalents and investments |
53,239 | 48,433 | 43,322 | |||||||||
|
Accounts receivable, net |
18,191 | 17,859 | 11,181 | |||||||||
|
Inventories |
16,913 | 15,672 | 14,702 | |||||||||
|
Other current assets and prepaid expenses |
2,840 | 2,403 | 2,619 | |||||||||
|
Total current assets |
91,183 | 84,367 | 71,824 | |||||||||
|
Property and equipment, net |
1,867 | 1,802 | 1,577 | |||||||||
|
Deferred tax asset |
381 | 394 | 401 | |||||||||
|
Intangibles, net |
- | - | 44 | |||||||||
|
Goodwill |
1,339 | 1,339 | 1,339 | |||||||||
|
Other long-term assets |
381 | 389 | 448 | |||||||||
|
Total assets |
$ | 95,151 | $ | 88,291 | $ | 75,633 | ||||||
|
Liabilities and Stockholders' Equity |
||||||||||||
|
Current liabilities: |
||||||||||||
|
Accounts payable |
$ | 4,293 | $ | 3,089 | $ | 2,752 | ||||||
|
Accrued liabilities |
18,973 | 14,950 | 13,201 | |||||||||
|
Deferred revenue |
8,901 | 8,275 | 8,919 | |||||||||
|
Total current liabilities |
32,167 | 26,314 | 24,872 | |||||||||
|
Deferred revenue, net of current portion |
1,982 | 1,801 | 1,685 | |||||||||
|
Income tax liability |
170 | 169 | 157 | |||||||||
|
Other long-term liabilities |
604 | 565 | 587 | |||||||||
|
Total liabilities |
34,923 | 28,849 | 27,301 | |||||||||
|
Stockholders' equity |
60,228 | 59,442 | 48,332 | |||||||||
|
Total liabilities and stockholders' equity |
$ | 95,151 | $ | 88,291 | $ | 75,633 | ||||||
|
CUTERA, INC. |
||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||||
|
(in thousands) |
||||||||||
|
(unaudited) |
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
June 30, |
June 30, |
June 30, |
June 30, |
|||||||||||||
|
2017 |
2016 |
2017 |
2016 |
|||||||||||||
|
Cash flows from operating activities: |
||||||||||||||||
|
Net income (loss) |
$ | 1,947 | $ | (1,229 | ) | $ | 925 | $ | (3,280 | ) | ||||||
|
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
||||||||||||||||
|
Stock-based compensation |
1,231 | 750 | 2,626 | 2,082 | ||||||||||||
|
Depreciation and amortization |
244 | 244 | 492 | 484 | ||||||||||||
|
Other |
6 | (75 | ) | (45 | ) | (63 | ) | |||||||||
|
Changes in assets and liabilities: |
||||||||||||||||
|
Accounts receivable |
(336 | ) | (8 | ) | (1,641 | ) | 464 | |||||||||
|
Inventories |
(1,241 | ) | (1,227 | ) | (1,936 | ) | (2,624 | ) | ||||||||
|
Accounts payable |
1,204 | 182 | 1,695 | 793 | ||||||||||||
|
Accrued liabilities |
4,191 | 1,985 | 1,534 | (773 | ) | |||||||||||
|
Deferred revenue |
807 | (218 | ) | 784 | (321 | ) | ||||||||||
|
Other |
(378 | ) | (712 | ) | (544 | ) | (1,114 | ) | ||||||||
|
Net cash provided by (used in) operating activities |
7,675 | (308 | ) | 3,890 | (4,352 | ) | ||||||||||
|
Cash flows from investing activities: |
||||||||||||||||
|
Acquisition of property, equipment and software |
(141 | ) | (40 | ) | (210 | ) | (137 | ) | ||||||||
|
Disposal of property and equipment |
15 | 6 | 40 | 6 | ||||||||||||
|
Net change in marketable investments |
2,385 | 2,257 | 5,703 | 1,633 | ||||||||||||
|
Net cash provided by investing activities |
2,259 | 2,223 | 5,533 | 1,502 | ||||||||||||
|
Cash flows from financing activities: |
||||||||||||||||
|
Repurchases of common stock |
(4,341 | ) | (2,586 | ) | (7,041 | ) | (2,865 | ) | ||||||||
|
Proceeds from exercise of stock options and employee stock purchase plan |
2,120 | 2,206 | 3,871 | 2,950 | ||||||||||||
| Taxes paid related to net share settlement of equity awards | (383 | ) | (323 | ) | (1,167 | ) | (556 | ) | ||||||||
|
Payments on capital lease obligations |
(94 | ) | (57 | ) | (182 | ) | (127 | ) | ||||||||
|
Excess tax benefit related to stock-based compensation |
— | — | — | — | ||||||||||||
|
Net cash used in financing activities |
(2,698 | ) | (760 | ) | (4,519 | ) | (598 | ) | ||||||||
|
Net increase (decrease) in cash and cash equivalents |
7,236 | 1,155 | 4,904 | (3,448 | ) | |||||||||||
|
Cash and cash equivalents at beginning of period |
11,443 | 6,265 | 13,775 | 10,868 | ||||||||||||
|
Cash and cash equivalents at end of period |
$ | 18,679 | $ | 7,420 | $ | 18,679 | $ | 7,420 | ||||||||
|
CUTERA, INC. |
|||||||||||||
|
CONSOLIDATED FINANCIAL HIGHLIGHTS |
|||||||||||||
|
(in thousands, except percentage data) |
|||||||||||||
|
(unaudited) |
|
Three Months Ended |
% Change |
Six Months Ended |
% Change |
|||||||||||||||||||||
|
Q2 |
Q2 |
Q2 '17 Vs |
Q2 |
Q2 |
YTD Q2 '17 Vs |
|||||||||||||||||||
|
2017 |
2016 |
Q2 '16 |
2017 |
2016 |
YTD Q2 '16 |
|||||||||||||||||||
|
Revenue By Geography: |
||||||||||||||||||||||||
|
United States |
$ | 24,239 | $ | 15,806 |
+53% |
$ | 40,783 | $ | 26,860 |
+52% |
||||||||||||||
|
International |
12,150 | 11,671 |
+4% |
24,905 | 23,040 |
+8% |
||||||||||||||||||
| $ | 36,389 | $ | 27,477 |
+32% |
$ | 65,688 | $ | 49,900 |
+32% |
|||||||||||||||
|
International as a percentage of total revenue |
33% | 42% | 38% | 46% | ||||||||||||||||||||
|
Revenue By Product Category: |
||||||||||||||||||||||||
|
Products |
||||||||||||||||||||||||
|
-North America |
$ | 22,626 | $ | 13,888 |
+63% |
$ | 37,086 | $ | 22,912 |
+62% |
||||||||||||||
|
-International |
7,489 | 6,976 |
+7% |
16,021 | 14,465 |
+11% |
||||||||||||||||||
|
Total Products |
30,115 | 20,864 |
+44% |
53,107 | 37,377 |
+42% |
||||||||||||||||||
|
Service |
4,662 | 5,023 | -7% | 9,486 | 9,490 | -0% | ||||||||||||||||||
|
Hand Piece Refills |
649 | 720 | -10% | 1,148 | 1,284 | -11% | ||||||||||||||||||
|
Skincare |
963 | 870 |
+11% |
1,947 | 1,749 |
+11% |
||||||||||||||||||
| $ | 36,389 | $ | 27,477 |
+32% |
$ | 65,688 | $ | 49,900 |
+32% |
|||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||
|
Q2 |
Q2 |
Q2 |
Q2 |
|||||||||||||
|
2017 |
2016 |
2017 |
2016 |
|||||||||||||
|
Pre-tax Stock-Based Compensation Expense: |
||||||||||||||||
|
Cost of revenue |
$ | 147 | $ | 40 | $ | 276 | $ | 181 | ||||||||
|
Sales and marketing |
401 | 229 | 821 | 605 | ||||||||||||
|
Research and development |
239 | 105 | 476 | 285 | ||||||||||||
|
General and administrative |
444 | 376 | 1,053 | 1,011 | ||||||||||||
| $ | 1,231 | $ | 750 | $ | 2,626 | $ | 2,082 | |||||||||